Effectiveness of the use of a high-flow nasal cannula to treat COVID-19 patients and risk factors for failure: a meta-analysis
| Autor: | Dong-yang Xu, Bing Dai, Wei Tan, Hong-wen Zhao, Wei Wang, Jian Kang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Therapeutic Advances in Respiratory Disease, Vol 16 (2022) |
| Druh dokumentu: | article |
| ISSN: | 1753-4666 17534666 |
| DOI: | 10.1177/17534666221091931 |
| Popis: | Background: Coronavirus disease 2019 (COVID-19) has spread globally, and many patients with severe cases have received oxygen therapy through a high-flow nasal cannula (HFNC). Objectives: We assessed the efficacy of HFNC for treating patients with COVID-19 and risk factors for HFNC failure. Methods: We searched PubMed, Embase, and the Cochrane Central Register of randomized controlled trials (RCTs) and observational studies of HFNC in patients with COVID-19 published in English from January 1st, 2020 to August 15th, 2021. The primary aim was to assess intubation, mortality, and failure rates in COVID-19 patients supported by HFNC. Secondary aims were to compare HFNC success and failure groups and to describe the risk factors for HFNC failure. Results: A total of 25 studies fulfilled selection criteria and included 2851 patients. The intubation, mortality, and failure rates were 0.44 (95% confidence interval (CI): 0.38–0.51, I 2 = 84%), 0.23 (95% CI: 0.19–0.29, I 2 = 88%), and 0.47 (95% CI: 0.42–0.51, I 2 = 56%), respectively. Compared to the success group, age, body mass index (BMI), Sequential Organ Failure Assessment (SOFA) score, Acute Physiology and Chronic Health Evaluation (APACHE) II score, D-dimer, lactate, heart rate, and respiratory rate were higher and PaO 2 , PaO 2 /FiO 2 , ROX index (the ratio of SpO 2 /FiO 2 to respiratory rate), ROX index after the initiation of HFNC, and duration of HFNC were lower in the failure group (all Ps |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|